Status Report on Consensus Frameworks in the APEC Region

Prepared for the
2019 APEC Business Ethics for SMEs Forum
9-10 September │ Santiago de Chile

Table of Contents:

<table>
<thead>
<tr>
<th>Economy</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia</td>
<td>2-6</td>
</tr>
<tr>
<td>Canada</td>
<td>7</td>
</tr>
<tr>
<td>China</td>
<td>8-9</td>
</tr>
<tr>
<td>Japan</td>
<td>10</td>
</tr>
<tr>
<td>Mexico</td>
<td>11-12</td>
</tr>
<tr>
<td>Peru</td>
<td>13-15</td>
</tr>
<tr>
<td>The Philippines</td>
<td>16-17</td>
</tr>
<tr>
<td>Viet Nam</td>
<td>18</td>
</tr>
<tr>
<td>Consensus Framework Name</td>
<td>Australian Ethical Health Alliance (AEHA), formerly referred to as the Australian Consensus Framework for Ethical Collaboration in the Healthcare Sector</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Year Proposed</td>
<td>2017 (at APEC Business Ethics for SMEs Forum)</td>
</tr>
<tr>
<td>Date Launched (Month/Year)</td>
<td>July 2018</td>
</tr>
<tr>
<td>Current Number of Parties</td>
<td>71</td>
</tr>
<tr>
<td>Stakeholder Participants (Check all that Apply)</td>
<td>X Medical Device Industry X Biopharmaceutical Industry X Third Parties / Distributors X Healthcare Professionals X Patient Organizations X Government Authorities X Hospitals / Healthcare Centers X Additional Stakeholders Not Listed</td>
</tr>
</tbody>
</table>
| Complete List of Parties (Full Names of Each Organization) | Arthroplasty Society of Australia  
Assistive Technology Suppliers Australia  
Audiology Australia  
Australasian College of Cosmetic Surgery  
Australasian College of Dermatologists  
Australasian College of Health Service Management  
Australasian College of Phlebology  
Australasian College of Sport and Exercise Physicians  
Australasian Leukemia and Lymphoma Group  
Australasian Sleep Association  
Australian and New Zealand Association of Oral and Maxillofacial Surgeons  
Australian and New Zealand College of Anaesthetists  
Australian and New Zealand College of Paramedicine  
Australian and New Zealand Melanoma Trials Group  
Australian and New Zealand Sarcoma Association  
Australian and New Zealand Society for Geriatric Medicine  
Australian and New Zealand Society for Vascular Surgery  
Australian and New Zealand Society of Cardiac and Thoracic Surgeons  
Australian and New Zealand Urogenital and Prostate Cancer Trials Group Ltd  
Australian College of Emergency Medicine  
Australian College of Nursing  
Australian Dental Association  
Australian Hand Surgery Society  
Australian Healthcare and Hospitals Association  
Australian Knee Society  
Australian Orthopaedic Association  
Australian Orthopaedic Association Medical Legal Society  
Australian Orthopaedic Foot and Ankle Society  
Australian Orthopaedic Trauma Society  
Australian Paediatric Orthopaedic Society  
Australian Pharmacy Council  
Australian Private Hospitals Association  
Australian Society of Anaesthetists  
Australian Society of Clinical Immunology and Allergy  
Australian Society of Ophthalmologists  
Australian Society of Otolaryngology Head and Neck Surgery  
Australian Society of Plastic Surgeons  
Australian Traditional Medicine Society  
Breast Cancer Trials  
BUPA  
Complementary Medicines Australia  |
| Have Framework meetings occurred since launch? | Yes. Dates: 13 January 2019, 5 April 2019, 19 July 2019 |
| List Parties who attended the last two Framework meetings | **January meeting** (35 parties):
- Apex Consulting
- Audiology Australia
- Australasian College of Phlebology
- Australasian College of Sport and Exercise Physicians
- Australia and New Zealand Melanoma Trials Group
- Australia and New Zealand Vascular Society
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Australian Healthcare and Hospitals Association
- Australian Knee Society
- Australian Medical Council
- Australian Medical Manufacturers and Distributors Association
- Australian Orthopaedic Association
- Australian Self Medication Industry
- Australian Society of Plastic Surgeons
- Australian Traditional Medicine Society
- Bupa
- Calvary Health Care
- Consumer Health Forum
- Cosmetic Physicians College of Australia |
Department of Health
Gastroenterological Society of Australia
Medical Technology Association of Australia
Medicines Australia
NSW Ministry of Health
Pharmacy Council of Australia
Praxis Australia
Private Healthcare Australia
Royal Australasian College of Surgeons
Royal Australian and New Zealand College of Ophthalmologists
Royal Australian and New Zealand College of Psychiatrists
Royal Australian College of General Practitioners
Society of Hospital Pharmacists of Australia
Therapeutic Goods Administration
Universities Australia
Urological Society of Australia & New Zealand

**April meeting** (20 parties):
Australian Orthopaedic Association
Department of Health
Australian Healthcare and Hospitals Association
Australasian Sleep Association
Assistive Technology Suppliers Australia
Medicines Australia
Cosmetic Physicians College of Australasia
Australian Society of Plastic Surgeons
Skin Cancer College Australasia
Musculoskeletal Australia
Avant
Australasian College of Sport and Exercise Physicians
General Surgeons Australia
Private Healthcare Australia
Australian Orthopaedic Association
Consumers Health Forum
MIGA
Australian College of Rural and Remote Medicine
ACT Health Directorate
Audiology Australia

**July meeting** (15 parties):
Australasian College of Cosmetic Surgery
Australian College of Nursing
Australian Healthcare and Hospitals Association
Australian Orthopaedic Association
Australian Pharmacy Council
Australian Society of Plastic Surgeons
Bupa
Canberra Hand Centre
Consumer Health Forum of Australia
Department of Health
General Surgeons Australia
MIGA
NPS MedicineWise
| Painaustralia  
<table>
<thead>
<tr>
<th>Skin Cancer College</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Are future Framework meetings planned?</strong></td>
</tr>
<tr>
<td><strong>Yes / Please indicate future dates here:</strong> TBC in 2020 (annual basis) with the AEHA Steering Committee likely meet four times per year.</td>
</tr>
<tr>
<td><strong>Describe the priorities and activities of the Framework</strong></td>
</tr>
<tr>
<td>The <em>Australian Consensus Framework for Ethical Collaboration in the Healthcare Sector</em> (ACF) describes the values and ethical principles that should form the basis of collaboration and interaction among organisations in the Australian healthcare sector, and aims to:</td>
</tr>
<tr>
<td>• Promote collaboration and interaction among healthcare sector organisations and those who work within them that benefits patients, consumers, students, educators, communities, populations, healthcare systems and the healthcare sector.</td>
</tr>
<tr>
<td>• Encourage better dialogue, trust and respect between and amongst organisations in and working with the healthcare sector.</td>
</tr>
<tr>
<td>• Enhance the integrity and trustworthiness of organisations in the healthcare sector.</td>
</tr>
<tr>
<td>• Promote public confidence and trust in healthcare sector organisations by demonstrating a shared commitment to integrity and ethics.</td>
</tr>
<tr>
<td>All signatories to the ACF have join a combined alliance: the Australian Ethical Health Alliance (AEHA). The ACF aims are supported by the AEHA Implementation Plan, where implementation activity has already commenced in many areas (detailed in the attachment).</td>
</tr>
<tr>
<td><strong>Indicate any learnings from the Framework to-date</strong></td>
</tr>
<tr>
<td>Through the development of the Framework, the AEHA has learnt that each member organisation has a different reason for joining as a signatory and that the principles outlined in the ACF will be more or less salient to different organisations depending upon their membership, structure and remit.</td>
</tr>
<tr>
<td>While the ACF provides a good basis for promoting ethical collaboration, practical changes to an organisation’s ethical practice and culture requires clear directions on how to implement the ethical principles. As such, the collective AEHA group have begun to develop a <em>Guide for Member Organisations</em> that provides suggestions as to how organisations might align their practices and policies with the ACF principles.</td>
</tr>
<tr>
<td>Many member organisations felt that implementation strategies would assist in delivering changes in ethical collaboration. It was stressed that the strategies could not be too prescriptive, but should provide practical advice and examples on how to enact the different principles. Through this document, member organisations are encouraged to implement as many strategies as possible, and to generate their own implementation strategies that could be shared amongst AEHA members.</td>
</tr>
<tr>
<td>The AEHA has also learnt that a useful approach to ensuring that the ACF principles are enacted is for all AEHA member organisations is through the development of an annual self-evaluation form. This self-evaluation form, included in the <em>Guide for Member Organisations</em>, encourages members to monitor their progress on implementing the ethical principles and will provide a tool for monitoring progress made against each of the ACF principles.</td>
</tr>
</tbody>
</table>
The Australian Ethical Health Alliance (AEHA) would recommend to other economies that each step in the development and implementation of a Framework be voluntary, consultative and collaborative. AEHA has seen adoption success through all activities being led by member-organisation decisions, with all member organisations being given equal opportunities to take part in decisions and projects.

AEHA would also recommend that each of the overarching principles be developed with an awareness of a potential broad-spectrum member group, so that a wide variety of member organisations will be able to adopt the principles. A pilot of ethical strategies could also be included to validate that the implementation strategies are relevant to all stakeholders.

The AEHA has also not set any requirements on becoming a Framework signatory and recommends that other economies adopt this approach. For AEHA, this has meant that a large range of stakeholders can join AEHA regardless of the stage they are at in their ethical journey. Including organisations with different levels of progress on implementing ethical practice has meant that learnings and experiences can be shared.

<table>
<thead>
<tr>
<th>List of Parties who Reviewed / Provided Input to this Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrian Cosenza – Chair ACF and on behalf of the AEHA leadership team</td>
</tr>
<tr>
<td>Talysa Trevallion – AEHA Project Officer</td>
</tr>
<tr>
<td><strong>Consensus Framework Name</strong></td>
</tr>
<tr>
<td>----------------------------</td>
</tr>
<tr>
<td><strong>Year Proposed</strong></td>
</tr>
<tr>
<td><strong>Date Launched (Month/Year)</strong></td>
</tr>
<tr>
<td><strong>Current Number of Parties</strong></td>
</tr>
<tr>
<td><strong>Stakeholder Participants (Check all that Apply)</strong></td>
</tr>
</tbody>
</table>
  □ Medical Device Industry  
  □ Third Parties / Distributors  
  □ Patient Organizations  
  □ Hospitals / Healthcare Centers  
  □ Biopharmaceutical Industry  
  □ Healthcare Professionals  
  □ Government Authorities  
  □ Additional Stakeholders Not Listed |
| **Complete List of Parties (Full Names of Each Organization)** |  
  - Best Medicines Coalition (BMC)  
  - Canadian Medical Association (CMA)  
  - Canadian Nurses Association (CNA)  
  - Canadian Pharmacists Association (CPhA)  
  - Consumer Health Products Canada  
  - Health Charities Coalition of Canada (HCCC)  
  - Innovative Medicines Canada (IMC) |
| **Have Framework meetings occurred since launch?** | □ X Yes / Please indicate dates here: June 28, 2018, December 19, 2018  
  May 14, 2019, June 14, 2019 |
| **List Parties who attended the last two Framework meetings** |  
  - Best Medicines Coalition (BMC)  
  - Canadian Nurses Association (CNA)  
  - Canadian Medical Association (CMA)  
  - Consumer Health Products Canada (CPhA)  
  - Global Affairs Canada  
  - Health Charities Coalition of Canada (HCCC)  
  - Innovative Medicines Canada  
  - Public Health Agency of Canada |
| **Are future Framework meetings planned?** | □ Yes / Please indicate future dates here:  
  □ X Yes / Date Not Scheduled - Fall 2019, Winter 2020  
  □ No |
| **Describe the priorities and activities of the Framework** |  
  - Enhance credibility and encourage better dialogue, trust and respect between patient organizations, health care professionals, the pharmaceutical industry and governments.  
  - Create an environment for signatories of the framework to have authentic discussions about improving health care and patient outcomes. |
| **Indicate any learnings from the Framework to-date** |  
  - Members have often stated that while this is not a framework for regulation, it does serve as an important mechanism for initiating safe discussions on health care reform and public policy debates.  
  - Signatories to the framework utilize ongoing meetings to drive collaboration and learning through ongoing review of changes to the individual member codes of ethics, use of case studies and identification of issues in risk areas. |
| **Please describe any advice for other economies as they pursue Framework adoption and implementation** |  
  - Emphasis is on enabling a collaboration model vs. anti-corruption model.  
  - Value of co-development of initial or revised frameworks with patient organizations. |
<p>| <strong>List of Parties who Reviewed / Provided Input to this Form</strong> | IMC, CNA, BMC, HCCC |</p>
<table>
<thead>
<tr>
<th>Consensus Framework Name</th>
<th>Chinese Consensus Framework for the Ethical Collaboration in the Pharmaceutical and Medical Device Sectors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year Proposed</td>
<td>2017</td>
</tr>
<tr>
<td>Date Launched (Month/Year)</td>
<td>07/2018</td>
</tr>
<tr>
<td>Current Number of Parties</td>
<td>25</td>
</tr>
</tbody>
</table>
| Stakeholder Participants (Check all that Apply) | V Medical Device Industry V Biopharmaceutical Industry  
V Third Parties / Distributors  
□ Patient Organizations  
□ Government Authorities  
V Hospitals / Healthcare Centers  
V Additional Stakeholders Not Listed |
| Complete List of Parties (Full Names of Each Organization) | China Pharmaceutical Industry Association (CPIA)  
China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE)  
R&D-based Pharmaceutical Association Committee of China Association of Enterprises with Foreign Investment (RDPAC)  
China Association of Traditional Chinese Medicine (CATCM)  
China Pharmaceutical Innovation and Research Development Association (PhIRDA)  
China Association of Pharmaceutical Commerce (CAPC)  
China Nonprescription Medicines Association (CNMA)  
Chinese Hospital Association (CHA)  
China Pharmaceutical Enterprises Development Promote Association (CPEP)  
China Association for Medical Devices Industry (CAMDI)  
China Medicinal Biotech Association (CMBA)  
China National Pharmaceutical Packaging Association (CNPPA)  
China Pharmaceutical Association of Plant Engineering (CPAPE)  
China Biochemical Pharmaceutical Industry Association (CBPIA)  
Chinese Non-government Medical Institutions Association (CNMIA)  
PSM Foundation  
Beijing Pharmaceutical Profession Association (BPPA)  
Shanghai Pharmaceutical Profession Association (SPPA)  
Hebei Pharmaceutical Profession Association (HBPPA)  
Shandong Pharmaceutical Profession Association (SDPPA)  
Jiangsu Pharmaceutical Profession Association (JSPPA)  
Shaanxi Pharmaceutical Profession Association (SPPA)  
Liaoning Pharmaceutical Profession Association (LNPPA)  
Fujian Pharmaceutical Profession Association (FJPPA)  
Zhejiang Pharmaceutical Industry Association (ZJPIA) |
| Have Framework meetings occurred since launch? | V Yes / Please indicate dates here: 03/06/2019  
□ No |
| List Parties who attended the last two Framework meetings | Ministry of Commerce  
IFPMA  
China Council for the Promotion of International Trade (CCPIT)  
China Pharmaceutical Industry Association (CPIA)  
China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE)  
R&D-based Pharmaceutical Association Committee of China Association of Enterprises with Foreign Investment (RDPAC)  
China Association of Traditional Chinese Medicine (CATCM)  
China Pharmaceutical Innovation and Research Development Association (PhIRDA) |
Chinese Hospital Association (CHA)
China Nonprescription Medicines Association (CNMA)
China Pharmaceutical Enterprises Development Promote Association (CPEP)
China Association for Medical Devices Industry (CAMDI)
China Medicinal Biotech Association (CMBA)
China National Pharmaceutical Packaging Association (CNPPA)
China Biochemical Pharmaceutical Industry Association (CBPIA)
Chinese Non-government Medical Institutions Association (CNMIA)
Beijing Pharmaceutical Profession Association (BPPA)
Shanghai Pharmaceutical Profession Association (SPPA)
Hebei Pharmaceutical Profession Association (HBPPA)
Merck
Luye Pharma Group
Eli Lilly and Company
Bayer
Novo Nordisk
Pfizer
Takeda
Betta Pharmaceutical Co., Ltd.
Qilu Pharmaceutical
Fosun Pharma
Innovent Bio

Are future Framework meetings planned?
☐ Yes / Please indicate future dates here:
√ Yes / Date Not Scheduled
☐ No

Describe the priorities and activities of the Framework
Priorities: People-Oriented, Strengthened Collaboration, Respecting Differences, Accountability;
Activities: Capacity Building & Training, Conduct Restriction, Timely Updates.

Indicate any learnings from the Framework to-date
It’s important to advance further collaboration with multi-stakeholders.
It’s necessary to identify a plan of action to advance code implementation and code harmonization together for China, including approaches for association training programs using a “train-the-trainer” approach.
There is mutual recognition that China will benefit from implementing ethical principles and foster a level playing field, and that strengthening ethical business practices across China’s pharmaceutical sector is aligned with embracing a patient-centric approach.

Please describe any advice for other economies as they pursue Framework adoption and implementation
1. Seek support from the government;
2. Collaborate with multi-stakeholders from both their own economy and other economies;
3. Strengthening awareness is the basis for pursuing the consensus framework.

List of Parties who Reviewed / Provided Input to this Form
China Pharmaceutical Industry Association (CPIA)
China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE)
<table>
<thead>
<tr>
<th><strong>Consensus Framework Name</strong></th>
<th>Japan Consensus Framework for Ethical Collaboration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Year Proposed</strong></td>
<td>2018</td>
</tr>
<tr>
<td><strong>Date Launched (Month/Year)</strong></td>
<td>July 2018</td>
</tr>
<tr>
<td><strong>Current Number of Parties</strong></td>
<td>8</td>
</tr>
<tr>
<td><strong>Stakeholder Participants (Check all that Apply)</strong></td>
<td>□ Medical Device Industry</td>
</tr>
<tr>
<td></td>
<td>□ Third Parties / Distributors</td>
</tr>
<tr>
<td></td>
<td>□ Patient Organizations</td>
</tr>
<tr>
<td></td>
<td>□ Hospitals / Healthcare Centers</td>
</tr>
<tr>
<td></td>
<td>□ Additional Stakeholders Not Listed</td>
</tr>
<tr>
<td><strong>Have Framework meetings occurred since launch?</strong></td>
<td>Yes / Please indicate dates here: 20 July 2018, 9 November 2018</td>
</tr>
<tr>
<td><strong>List Parties who attended the last two Framework meetings</strong></td>
<td><strong>20 July 2018:</strong> Japan Patients Association, The Federation of Pharmaceutical Manufacturers' Associations of Japan, The Japan Federation of Medical Devices Associations, Japan Medical Association</td>
</tr>
<tr>
<td><strong>Are future Framework meetings planned?</strong></td>
<td>Yes / Please indicate future dates here: 31 July 2019</td>
</tr>
<tr>
<td><strong>Describe the priorities and activities of the Framework</strong></td>
<td>Enhance awareness of the consensus framework.</td>
</tr>
<tr>
<td></td>
<td>Preparation for 2019 APEC meeting.</td>
</tr>
<tr>
<td><strong>Indicate any learnings from the Framework to-date</strong></td>
<td>Understand each stakeholders’ own ethical codes, policies and rules.</td>
</tr>
<tr>
<td><strong>Please describe any advice for other economies as they pursue Framework adoption and implementation</strong></td>
<td>As “Put Patients First” is the most important principle in the framework, it is a must to include a patient group.</td>
</tr>
<tr>
<td><strong>List of Parties who Reviewed / Provided Input to this Form</strong></td>
<td>Japan Patients Association, Japan Federation of Cancer Patient Groups, Japanese Nursing Association, The Federation of Pharmaceutical Manufacturers' Associations of Japan, The Japan Federation of Medical Devices Associations, Japan Pharmaceutical Association, Japan Medical Association</td>
</tr>
<tr>
<td>Consensus Framework Name</td>
<td>Compromiso por la Transparencia (Mexico Transparency Agreement)</td>
</tr>
<tr>
<td>--------------------------</td>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>Year Proposed</td>
<td>2007</td>
</tr>
<tr>
<td>Date Launched (Month/Year)</td>
<td>October 2007</td>
</tr>
<tr>
<td>Current Number of Parties</td>
<td>13</td>
</tr>
<tr>
<td>Stakeholder Participants (Check all that Apply)</td>
<td></td>
</tr>
<tr>
<td>X Medical Device Industry</td>
<td>X Biopharmaceutical Industry</td>
</tr>
<tr>
<td>□ Third Parties / Distributors</td>
<td>X Healthcare Professionals</td>
</tr>
<tr>
<td>□ Patient Organizations</td>
<td>X Government Authorities</td>
</tr>
<tr>
<td>X Hospitals / Healthcare Centers</td>
<td>X Additional Stakeholders Not Listed</td>
</tr>
<tr>
<td>Complete List of Parties (Full Names of Each Organization)</td>
<td></td>
</tr>
<tr>
<td>Academia Nacional de Medicina de México</td>
<td></td>
</tr>
<tr>
<td>Cámara Nacional de la Industria Farmacéutica en México</td>
<td></td>
</tr>
<tr>
<td>Comisión Nacional de Bioética</td>
<td></td>
</tr>
<tr>
<td>Consejo de Ética y Transparencia de la Industria Farmacéutica</td>
<td></td>
</tr>
<tr>
<td>Academia Mexicana de Cirugía</td>
<td></td>
</tr>
<tr>
<td>Academia Mexicana de Pediatría</td>
<td></td>
</tr>
<tr>
<td>Colegio Médico de México</td>
<td></td>
</tr>
<tr>
<td>Asociación Nacional de Hospitales Privados</td>
<td></td>
</tr>
<tr>
<td>Facultad de Medicina, Universidad Nacional Autónoma de México</td>
<td></td>
</tr>
<tr>
<td>Escuela Superior de Medicina, Instituto Politécnico Nacional</td>
<td></td>
</tr>
<tr>
<td>Instituto Mexicano del Seguro Social</td>
<td></td>
</tr>
<tr>
<td>Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado</td>
<td></td>
</tr>
<tr>
<td>Secretaría de Salud</td>
<td></td>
</tr>
<tr>
<td>Have Framework meetings occurred since launch?</td>
<td>X Yes / Please indicate dates here: At least twice per year</td>
</tr>
<tr>
<td>List Parties who attended the last two Framework meetings</td>
<td></td>
</tr>
<tr>
<td>Academia Nacional de Medicina de México</td>
<td></td>
</tr>
<tr>
<td>Cámara Nacional de la Industria Farmacéutica en México</td>
<td></td>
</tr>
<tr>
<td>Comisión Nacional de Bioética</td>
<td></td>
</tr>
<tr>
<td>Consejo de Ética y Transparencia de la Industria Farmacéutica (CETIFARMA)</td>
<td></td>
</tr>
<tr>
<td>Academia Mexicana de Cirugía</td>
<td></td>
</tr>
<tr>
<td>Academia Mexicana de Pediatría</td>
<td></td>
</tr>
<tr>
<td>Colegio Médico de México</td>
<td></td>
</tr>
<tr>
<td>Asociación Nacional de Hospitales Privados</td>
<td></td>
</tr>
<tr>
<td>Facultad de Medicina, Universidad Nacional Autónoma de México</td>
<td></td>
</tr>
<tr>
<td>Escuela Superior de Medicina, Instituto Politécnico Nacional</td>
<td></td>
</tr>
<tr>
<td>Instituto Mexicano del Seguro Social</td>
<td></td>
</tr>
<tr>
<td>Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado</td>
<td></td>
</tr>
<tr>
<td>Secretaría de Salud</td>
<td></td>
</tr>
<tr>
<td>Are future Framework meetings planned?</td>
<td>X Yes / Date Not Scheduled</td>
</tr>
<tr>
<td>Describe the priorities and activities of the Framework</td>
<td>- This year (2019) we are working with Authorities (General Council of Health) to update the Consensus Framework, including the invitation to Patients Organizations; and the link to the National Anticorruption System.</td>
</tr>
<tr>
<td>Indicate any learnings from the Framework to-date</td>
<td>- It is crucial to the correct functioning of any Consensus Framework to establish a follow up mechanism to solve breaches.</td>
</tr>
<tr>
<td>Please describe any advice for other economies as they pursue Framework adoption</td>
<td>- Take into account a follow up mechanism, a communication strategy and accountability since the beginning.</td>
</tr>
<tr>
<td>and implementation</td>
<td>CETIFARMA</td>
</tr>
<tr>
<td>--------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>List of Parties who Reviewed / Provided Input to this Form</td>
<td>CETIFARMA</td>
</tr>
<tr>
<td>Consensus Framework Name</td>
<td>Peruvian Consensus Framework for Multistakeholder Ethical Collaboration in the Pharmaceutical and Medical Device Sectors</td>
</tr>
<tr>
<td>--------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Year Proposed</td>
<td>2016</td>
</tr>
<tr>
<td>Date Launched (Month/Year)</td>
<td>September/2016</td>
</tr>
<tr>
<td>Current Number of Parties</td>
<td>22</td>
</tr>
</tbody>
</table>
| Stakeholder Participants (Check all that Apply) | x Medical Device Industry  x Biopharmaceutical Industry  
□ Third Parties / Distributors  x Healthcare Professionals  
x Patient Organizations  x Government Authorities  
□ Hospitals / Healthcare Centers  x Additional Stakeholders Not Listed |
| Complete List of Parties (Full Names of Each Organization) | 1.- Dirección General de Medicamentos, Insumos y Drogas- DIGEMID  
2.-Superintendencia Nacional de Salud- SUSALUD  
3.- Centro Nacional de Abastecimiento de Recursos Estratégicos en Salud- CENARES  
4.-Comision de Alto Nivel Anticorrupción- Presidencia del Consejo de Ministros  
5.-Sociedad de Comercio Exterior del Perú- COMEX Perú  
6.-Asociacion de Industrias Farmacéuticas Nacionales- ADIFAN  
7.-Confederacion Nacional de Instituciones Empresariales Privadas- CONFIEP  
8.-Comité de Productos para la Salud- COMSALUD –Cámara de Comercio de Lima  
9.- Asociación Nacional de Laboratorios Farmacéuticos- ALAFARPE  
10.-Asociacion de Laboratorios Farmacéuticos Latinoamericanos- ALAFAL  
11.-Asociacion Nacional de Cadenas de Boticas -ANACAB  
12.-Colegio Médico del Perú  
13.-Colegio Químico Farmacéutico del Perú  
14.-Asociacion de Clínicas Particulares del Perú  
15.-ESPERANTRA  
16.-Asociacion PROSA  
17.-Asociacion Benéfica PRISMA  
18.- Servicio de Medicinas PROVIDA  
19.-Red Peruana de Pacientes y Usuarios  
20.-Sociedad Peruana de Farmacia Hospitalaria  
21.-Accion Internacional para la Salud- AIS  
22.-MeTA Peru |
| Have Framework meetings occurred since launch? | x Yes / Please indicate dates here:  
2017: March 14, May 17, July 12,  
2018: July 12, August 24, September 27, November 28  
2019: March 4, May 2, June 6, July 11 |
| List Parties who attended the last two Framework meetings | 1.- Dirección General de Medicamentos, Insumos y Drogas- DIGEMID  
2.-Superintendencia Nacional de Salud- SUSALUD  
3.- Centro Nacional de Abastecimiento de Recursos Estratégicos en Salud- CENARES  
4.-Comision de Alto Nivel Anticorrupción- Presidencia del Consejo de Ministros  
5.-Sociedad de Comercio Exterior del Perú- COMEX Perú  
6.-Comité de Productos para la Salud- COMSALUD –Cámara de Comercio de Lima  
7.- Asociación Nacional de Laboratorios Farmacéuticos- ALAFARPE  
8.-Asociacion de Laboratorios Farmacéuticos Latinoamericanos- ALAFAL  
9.-Asociacion Nacional de Cadenas de Boticas -ANACAB  
10.-Colegio Médico del Perú  
11.-Colegio Químico Farmacéutico del Perú  
12.-Asociacion de Clínicas Particulares del Perú  
13.-ESPERANTRA |
Are future Framework meetings planned?  
Yes / Please indicate future dates here: 2019: August 1, September 5, October 3, November 7 (the dates could change and should be confirmed before)

Describe the priorities and activities of the Framework

The priorities are as follows:

- Designate mechanisms to strengthen trust and facilitate open communication between the parties.
- To promote the development and convergence of the Codes of Ethics of the parties in accordance with the agreed framework and current legal system.
- To develop training programs shared between the Parties.
- To promote collaboration between the Parties to facilitate the timely identification of challenges and take advantage of solution opportunities.

About the activities, each two months face-to-face meetings have been held with the aim of maintaining fluid communication with the signatories, strengthening trust and open communication among all, listening to their progress and carrying out a self-assessment format of the codes of ethics of each of the Parties. The Self-Assessment format have been proposed in order to have the baseline data that allow us to build towards a convergence of the codes of ethics according to the agreed framework and the current legal system.

Indicate any learnings from the Framework to-date

1. The work in consensus requires meeting points and agreement of actors: Since the Parties have different lines of work, there are opportunities for improvement to carry out activities that involve all the signatories.
2. The institutional commitment promotes participation in action: To promote the participation of all signatories through the respective follow-up of each of the signatory’s developments, despite the rotation of officials and those responsible for the issue for all sectors.
3. The sum of efforts of committed actors allows the achievement of a common agenda: To establish an agenda including the progress of each of the signatories individually in order to share experiences and lessons learned with the other signatories.

Please describe any advice for other economies as they pursue Framework adoption and implementation

1. To promote and make efforts to maintain periodic and sustained communication between the Parties, in order to maintain the momentum, the essence and dynamism of the document.
2. To facilitate the participation of the Parties in the coordination meetings, taking into account the ideas and proposals of each one as well as submitting them to contributions from other participants.
3. To disseminate in the meetings the training activities on the ethical practices that each of the Parties has been working on.
4. The government participation as a facilitator in coordination with all participants.
5. The confluence of actors and points of view enriches the proposal in favor of the initiative.
6. The use technological and digital tools from each part to measure the application and progress.

List of Parties who Reviewed / Provided Input to this Form

1. Dirección General de Medicamentos, Insumos y Drogas - DIGEMID
2. Superintendencia Nacional de Salud - SUSALUD
3. Sociedad de Comercio Exterior del Perú - COMEX Perú
4. Asociación de Industrias Farmacéuticas Nacionales - ADIFAN
5. Asociación Nacional de Laboratorios Farmacéuticos - ALAFARPE
6. Asociación Nacional de Cadenas de Boticas - ANACAB
<table>
<thead>
<tr>
<th>Número</th>
<th>Organización</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.</td>
<td>Colegio Médico del Perú</td>
</tr>
<tr>
<td>8.</td>
<td>Colegio Químico Farmacéutico del Perú</td>
</tr>
<tr>
<td>9.</td>
<td>Asociacion de Clínicas Particulares del Perú</td>
</tr>
<tr>
<td>10.</td>
<td>ESPERANTRA</td>
</tr>
<tr>
<td>11.</td>
<td>Asociacion Benéfica PRISMA</td>
</tr>
<tr>
<td>12.</td>
<td>Servicio de Medicinas PROVIDA</td>
</tr>
<tr>
<td>Consensus Framework Name</td>
<td>Philippines Consensus Framework for Ethical Collaboration</td>
</tr>
<tr>
<td>-------------------------</td>
<td>----------------------------------------------------------</td>
</tr>
<tr>
<td>Year Proposed</td>
<td>2018</td>
</tr>
<tr>
<td>Date Launched (Month/Year)</td>
<td>November 2018</td>
</tr>
<tr>
<td>Current Number of Parties</td>
<td>17 (plus others that committed but have not signed)</td>
</tr>
</tbody>
</table>
| Stakeholder Participants *(Check all that Apply)* | X Medical Device Industry  
□ Third Parties / Distributors  
X Patient Organizations  
□ Government Authorities  
X Hospitals / Healthcare Centers  
X Biopharmaceutical Industry  
X Healthcare Professionals  
X Additional Stakeholders Not Listed |
| Complete List of Parties *(Full Names of Each Organization)* | 1. Philippine Alliance of Patient Organizations (PAPO)  
2. Philippine Medical Association (PMA)  
3. Philippine Pharmacists Association (PPhA)  
4. Philippine Nurses Association (PNA)  
5. Pharmaceutical and Healthcare Association of the Philippines (PHAP)  
6. Association of Nursing Service Administrators of the Philippines (for ceremonial signing)  
7. Institute for Solidarity in Asia (ISA)  
8. Philippine Association of Medical Device Regulatory Affairs Professionals (PAMDRAP)  
9. Medicines Transparency Alliance (MeTA)  
10. Region 1 Medical Center (R1MC)  
11. Mariano Marcos Memorial Hospital and Medical Center  
12. Tondo Medical Center  
13. Navotas City Hospital  
14. Southern Philippines Medical Center (SPMC)  
15. Ilocos Training and Regional Medical Center (ITRMC)  
16. Philippine Hospitals Association *(for ceremonial signing)*  
17. Dr. Paulino J. Garcia Memorial Research & Medical Center *(for ceremonial signing)* |
| Have Framework meetings occurred since launch? | X Yes / Please indicate dates here: 27 November 2018 / 23 August 2019  
□ No |
| List Parties who attended the last two Framework meetings | Philippine Alliance of Patient Organizations (PAPO)  
Philippine Medical Association  
Philippine Nurses Association  
Pharmaceutical and Healthcare Association of the Philippines (PHAP)  
Philippine Pharmacists Association  
Philippine College of Physicians (PCP)  
Philippine Association of Medical Device Regulatory Affairs Professionals (PAMDRAP)  
Medicines Transparency Alliance (MeTA Philippines)  
Philippine Orthopaedic Association, Inc.  
Unilab *(Local pharmaceutical company)* |
| Are future Framework meetings planned? | X Yes / Please indicate future dates here: September / October 2019  
□ No |
| Describe the priorities and activities of the Framework | Priorities: Strategic Planning Session  
1) Gather endorsers / signatories through presentations in various fora and one-on-one meetings  
2) Include government and organizations from various parts of the country as signatories / endorsers |
<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>3)</td>
<td>Localize the global framework</td>
</tr>
<tr>
<td>4)</td>
<td>Build up information and education resources to build awareness</td>
</tr>
<tr>
<td>5)</td>
<td>Craft a communication plan including development of spokespersons</td>
</tr>
<tr>
<td>6)</td>
<td>Develop a seal/ logo</td>
</tr>
<tr>
<td><strong>Indicate any learnings from the Framework to-date</strong></td>
<td>1) The endorsements of major organizations such as the Philippine Medical Association, Philippine Alliance of Patient Organizations and Philippine Nurses Association pave the way for other organizations to join in the campaign</td>
</tr>
<tr>
<td></td>
<td>2) The leadership of APEC Business Ethics also provides more credibility into the advocacy</td>
</tr>
<tr>
<td></td>
<td>3) It is crucial to have a core group which will give overall directions and seek awareness opportunities for the framework collaboration</td>
</tr>
<tr>
<td></td>
<td>4) In raising and sustaining awareness, it is desirable to have signatories/ endorsers from various parts of the country</td>
</tr>
<tr>
<td><strong>Please describe any advice for other economies as they pursue Framework adoption and implementation</strong></td>
<td>1) Prioritize counterpart umbrella organizations of the Global Consensus Framework (local IAPO, WMA, IFPMA, ICN). Their endorsements will open doors for other organizations</td>
</tr>
<tr>
<td></td>
<td>2) Cite leadership of APEC Business Ethics when speaking with potential signatories</td>
</tr>
<tr>
<td></td>
<td>3) The global consensus framework could be the initial anchor for the campaign</td>
</tr>
<tr>
<td><strong>List of Parties who Reviewed / Provided Input to this Form</strong></td>
<td>Mr. Teodoro B. Padilla</td>
</tr>
<tr>
<td></td>
<td>Executive Director / PHAP</td>
</tr>
<tr>
<td><strong>Consensus Framework Name</strong></td>
<td>Vietnam Consensus Framework for Ethical Collaboration in Pharmaceutical and Medical Device Sectors</td>
</tr>
<tr>
<td>----------------------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Year Proposed</strong></td>
<td>2017</td>
</tr>
<tr>
<td><strong>Date Launched (Month/Year)</strong></td>
<td>September 2017</td>
</tr>
<tr>
<td><strong>Current Number of Parties</strong></td>
<td>9</td>
</tr>
</tbody>
</table>

**Stakeholder Participants (Check all that Apply)**
- ☑ Medical Device Industry
- ☑ Biopharmaceutical Industry
- ☑ Third Parties / Distributors
- ☑ Healthcare Professionals
- ☑ Patient Organizations
- ☑ Government Authorities
- ☑ Hospitals / Healthcare Centers
- ☑ Additional Stakeholders Not Listed

**Complete List of Parties (Full Names of Each Organization)**
- Vietnam Medical Association
- Vietnam Women Union
- Vietnamese Pharmaceutical Association
- Vietnam Pharmaceutical Companies Association
- Vietnam Medical Equipment Association
- Healthcare Committee, American Chamber of Commerce in Vietnam
- Pharma Group, EuroCham
- International Quality Medicines - Generic & Biosimilar (former International Quality Generics Sector Committee), EuroCham
- Medical Devices and Diagnostics, EuroCham

**Have Framework meetings occurred since launch?**
- ☑ No

**Are future Framework meetings planned?**
- ☑ Yes / Please indicate future dates here: Quarter 3, 2019
- ☐ Yes / Date Not Scheduled
- ☐ No

**Describe the priorities and activities of the Framework**
- Pharmaceutical and Medical Device Industry associations – foreign and local – to adopt industry self-regulated Codes of Ethics with the same high ethical standards, in line with the APEC Mexico City Principles, and share Codes of Ethics with other partners in healthcare;
- Organize dialogues with all stakeholders in healthcare, including the medical community, to promote high ethical standards.

**Indicate any learnings from the Framework to-date**
- The Framework has created a platform for industry associations to discuss revision of Codes of Ethics, towards having the same standards across different Codes.

**Please describe any advice for other economies as they pursue Framework adoption and implementation**
- Having Government representatives witness the signing & adoption of the Framework will help towards implementation
- Having meetings scheduled as soon as the Framework is signed
- All signatories to nominate key contact points and take turn (yearly) to coordinate the activities under the Framework

**List of Parties who Reviewed / Provided Input to this Form**
- Pharma Group, EuroCham
- IQMED Generic & Biosimilar, EuroCham
- MDD SC, EuroCham